HealthFDA Approves Rydapt For Treatment Of Acute Myeloid Leukemia In Adult Patients The FDA approved the Novartis AG's Rydapt on April 28. The drug is targeted toward AML patients and the FDA lists it for $22,500 for an average 42-day treatment.by Andrew Norman
HealthMarijuana-Laced Edible Sickens Dog: Signs Of Marijuana Poisoning In Animals Pet Owners Should Watch Out Forby Allan Adamson
HealthCan Human Head Transplant Become A Reality? Scientist Plans To Test Procedure By December 2017by Allan Adamson
HealthPeople With Slender Face Likely To Be Left-Handed, More Susceptible To Tuberculosisby Allan Adamson
HealthRice University Engineering Students Develop An Algorithm That Effectively Predicts And Prevents Seizuresby Luan Chan
HealthMinnesota Health Officials Face Opposition From Anti-Vaccine Activists Over Measles Vaccinationby Andrew Norman
HealthBioMarin's Brineura Gets FDA Approval As First Treatment For Type Of Batten Diseaseby Allan Adamson